3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one
• 英文别名: 3-(2-Chloropyrimidin-4-yl)-4-propan-2-yl-1,3-oxazolidin-2-one；3-(2-chloropyrimidin-4-yl)-4-propan-2-yl-1,3-oxazolidin-2-one
• 化学式: C₁₀H₁₂ClN₃O₂
• 分子量: 241.677
• InChiKey: CMYCIRFZJKISNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-噁唑烷酮,4-(1-甲基乙基)- 、 2,4-二氯嘧啶 在 sodium methansulfinate 、 四丁基溴化铵 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以73%的产率得到3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one
  参考文献：
  名称：

  2,4-二氯嘧啶和相关杂芳基氯化物的高区域选择性有机催化SN Ar胺化

  摘要：

  公开了一种使用亚磺酸钠和四丁基溴化铵作为催化剂的 2,4-二氯嘧啶与恶唑烷-2-one 和相关弱亲核胺的 SNAr 胺化的高效和区域选择性方法。该策略以区域和化学选择性方式促进各种氨基嘧啶的合成。该方法已成功用于各种活化的 N-杂芳族底物的胺化。

  DOI：

  10.1002/ejoc.201700459

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160083365A1

  公开（公告）日：2016-03-24

  The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W 1 , W 2 , W 3 , and R 1 -R 6 are described herein.

  这项发明涉及对突变异构异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，具有新陈代谢活性，可用于治疗细胞增殖紊乱和癌症，其化学式为：其中A、B、W1、W2、W3和R1-R6如本文所述。
• [EN] INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS D'ISOCITRATE DÉSHYDROGÉNASES MUTANTES, COMPOSITIONS ET PROCÉDÉS CORRESPONDANTS
  申请人：ISOCURE BIOSCIENCES INC

  公开号：WO2018118793A1

  公开（公告）日：2018-06-28

  The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

  该发明提供了用于治疗癌症或相关疾病或障碍的新型化合物，以及其制备和使用的药物组合物和方法。
• [EN] MUTANT IDH1 INHIBITORS<br/>[FR] INHIBITEURS DE LA IDH1 MUTANTE
  申请人：LILLY CO ELI

  公开号：WO2017213910A1

  公开（公告）日：2017-12-14

  The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.

  本申请提供了化合物的化学式I: 化学式(I)，这些化合物可用作突变IDH1的抑制剂，制药组合物，并用于治疗癌症。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2013046136A1

  公开（公告）日：2013-04-04

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formual (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式(I)的化合物或其药学上可接受的盐，其中R1-R6在此处被定义。该发明还涉及含有公式(I)化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式(I)的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。